Adial Pharmaceuticals announces annual shareholder meeting
Reuters2026/08/11 10:08- Adial Pharmaceuticals will hold its 2026 annual stockholder meeting in September 2026 in Charlottesville, Virginia.
- Votes are scheduled on issuing 12,930,617 common shares from conversion of Series A Non-Voting Convertible Preferred Stock tied to the Azora acquisition.
- Other items include approval to issue up to 1,177,782 shares from assumed Azora options, up to 11,780,948 shares from Initial Closing Pre-Funded Warrants.
- Stockholders will also vote on issuing up to 23,561,896 shares from Milestone Pre-Funded Warrants and Milestone Incentive Warrants, plus raising authorized common shares to 500,000,000.
- Additional proposals cover issuing up to 552,940 shares from Series F warrants, amending the 2017 equity plan, adopting 2026 equity plan and 2026 employee stock purchase plan.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Securitize to Help Develop Dubai’s Regulated Tokenized Asset Market
Audley Travel to open concessions in nine John Lewis stores from November 2026
Tessin Nordic Holding announces extraordinary shareholder meeting
Will a 10-year US Treasury yield rising to 5.5% "attack" US stocks? Societe Generale warns: this could be the valuation tipping point.
Bokobza, Global Head of Asset Allocation at Société Générale, pointed out that if the 10-year U.S. Treasury yield reaches 5.5%, corporate profit growth will not be sufficient to offset the impact of rising rates on valuations, and the stock market will face substantial pressure. However, he believes that the upcoming rate hikes by the Federal Reserve and the European Central Bank will be relatively limited and will not disrupt the current economic cycle.
Crypto prices
More
